• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Assembly Biosciences Inc.

    8/6/25 4:23:22 PM ET
    $ASMB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ASMB alert in real time by email
    S-8 1 asmb-20250806.htm S-8 S-8

    As filed with the Securities and Exchange Commission on August 6, 2025

     

    Registration No. 333-

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    FORM S-8

    REGISTRATION STATEMENT UNDER
    THE SECURITIES ACT OF 1933

    Assembly Biosciences, Inc.

    (Exact name of registrant as specified in its charter)

    Delaware

    20-8729264

    (State or other jurisdiction of
    incorporation or organization)

    (I.R.S. Employer
    Identification No.)

    Two Tower Place, 7th Floor
    South San Francisco, California

    94080

    (Address of Principal Executive Offices)

    (Zip Code)

    Assembly Biosciences, Inc. Amended and Restated 2018 Stock Incentive Plan

    Assembly Biosciences, Inc. Second Amended and Restated 2018 Employee Stock Purchase Plan

    (Full title of the plan)

    Jason A. Okazaki

    Chief Executive Officer and President

    Assembly Biosciences, Inc.

    Two Tower Place, 7th Floor
    South San Francisco, California 94080

    (Name and address of agent for service)

    (833) 509-4583

    (Telephone number, including area code, of agent for service)

    Copies to:

    P. Michelle Gasaway, Esq.

    Skadden, Arps, Slate, Meagher & Flom LLP

    300 South Grand Avenue, Suite 3400

    Los Angeles, California 90071

    (213) 687-5000

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

    Large accelerated filer ☐

    Accelerated filer ☐

    Non-accelerated filer ☒

    Smaller reporting company ☒

     

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     

     


     

    EXPLANATORY NOTE

    Pursuant to General Instruction E to Form S-8 under the Securities Act, this Registration Statement is being filed by Assembly Biosciences, Inc. (the “Company” or the “Registrant”) for the purpose of registering additional shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”) under (1) the Assembly Biosciences, Inc. Amended and Restated 2018 Stock Incentive Plan (the “2018 Plan”) and (2) the Assembly Biosciences, Inc. Second Amended and Restated 2018 Employee Stock Purchase Plan (the “2018 ESPP”).

    On April 23, 2024, the Company filed with the Securities and Exchange Commission (the “Commission”) a definitive proxy statement (the “Proxy Statement”) that included separate proposals to increase the number of shares reserved for issuance under the 2018 Plan by (1) 375,000 shares of Common Stock for general purposes and (2) 225,000 shares of Common Stock for issuance solely in connection with a supplemental retention program. This Registration Statement registers the 600,000 aggregate additional shares of Common Stock reserved for issuance under the 2018 Plan.

    The Proxy Statement also included a proposal to increase the number of shares reserved for issuance under the 2018 ESPP by 60,500 shares of Common Stock for issuance. This Registration Statement registers the 60,500 additional shares of Common Stock reserved for issuance under the 2018 ESPP.

    On February 9, 2024, we effectuated a 1-for-12 reverse stock split (the "Reverse Stock Split"), which also impacted the number of shares reserved for issuance under our equity plans. As a result of the Reverse Stock Split, as of February 9, 2024, the number of shares of Common Stock that were registered for issuance under the 2018 Plan was reduced from 10,600,000 shares to 833,333 shares, and the number of shares that were registered for issuance under the 2018 ESPP was reduced from 1,300,000 shares to 108,333 shares. Both plans were amended and restated in 2024, and additional shares for the two plans were registered pursuant to a Registration Statement on Form S-8 (Registration No. 333-281388) filed on August 8, 2024.

    Prior Registration Statements

    The 600,000 additional shares of Common Stock reserved for issuance under the 2018 Plan registered pursuant to this Registration Statement are of the same class of securities as the shares of Common Stock registered for issuance under the 2018 Plan pursuant to the following currently effective registration statements: (1) the Registration Statement on Form S-8 (Registration No. 333-226703) filed on August 8, 2018 (the “Original 2018 Plan Registration Statement”), (2) the Registration Statement on Form S-8 (Registration No. 333-233030) filed on August 5, 2019 (the “Second 2018 Plan Registration Statement”), (3) the Registration Statement on Form S-8 (Registration No. 333-248476) filed on August 28, 2020 (the “Third 2018 Plan Registration Statement”), (4) the Registration Statement on Form S-8 (Registration No. 333-258516) filed on August 5, 2021 (the “Fourth 2018 Plan Registration Statement”), (5) Registration Statement on Form S-8 (Registration No. 333-266711) filed on August 9, 2022 (the “Fifth 2018 Plan Registration Statement”), (6) Registration Statement on Form S-8 (Registration No. 333-273836) filed on August 9, 2023 (the "Sixth 2018 Plan Registration Statement") and (7) Registration Statement on Form S-8 (Registration No. 333-281388) (the "Amended and Restated 2018 Plan Registration Statement").

    The contents of the Original 2018 Plan Registration Statement, the Second 2018 Plan Registration Statement, the Third 2018 Plan Registration Statement, the Fourth 2018 Plan Registration Statement, the Fifth 2018 Plan Registration Statement, the Sixth 2018 Plan Registration Statement and the Amended and Restated 2018 Plan Registration Statement, including any amendments thereto or filings incorporated therein, are incorporated herein by reference. Any items in the Original 2018 Plan Registration Statement, the Second 2018 Plan Registration Statement, the Third 2018 Plan Registration Statement, the Fourth 2018 Plan Registration Statement, the Fifth 2018 Plan Registration Statement, the Sixth Registration Statement and the Amended and Restated 2018 Plan Registration Statement not expressly changed by this Registration Statement shall be as set forth in the Original 2018 Plan Registration Statement, the Second 2018 Plan Registration Statement, the Third 2018 Plan Registration Statement, the Fourth 2018 Plan Registration Statement, the Fifth 2018 Plan Registration Statement, the Sixth 2018 Plan Registration and the Amended and Restated 2018 Plan Registration Statement, as applicable.

    The 60,500 additional shares of Common Stock reserved for issuance under the 2018 ESPP registered pursuant to this Registration Statement are of the same class of securities as the shares of Common Stock registered for issuance under the 2018 ESPP pursuant to the following currently effective registration statements: (1) the Registration Statement on Form S-8 (Registration No. 333-226,703) filed on August 8, 2018 (the “Original 2018 ESPP Registration Statement”), (2) the Registration Statement on Form S-8 (Registration No. 333-258516) filed on August 5, 2021 (the “Amended and Restated 2018 ESPP Registration Statement”) and (3) the Registration

    1


     

    Statement on Form S-8 (Registration No. 333-281388) filed on August 8, 2024 (the “Second Amended and Restated 2018 ESPP”). The contents of the Original 2018 ESPP Registration Statement, the Amended and Restated 2018 ESPP Registration Statement and the Second Amended and Restated 2018 ESPP Registration Statement, including any amendments thereto or filings incorporated therein, are incorporated herein by reference. Any items in the Original 2018 ESPP Registration Statement, the Amended and Restated 2018 ESPP Registration Statement and the Second Amended and Restated 2018 ESPP Plan Registration Statement not expressly changed by this Registration Statement shall be as set forth in the Original 2018 ESPP Registration Statement, the Amended and Restated 2018 ESPP Registration Statement and the Second Amended and Restated 2018 ESPP Registration Statement, as applicable.

     

    2


     

    PART I

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

    The documents containing the information specified in Part I will be delivered in accordance with Form S-8 and Rule 428(b) under the Securities Act. Such documents are not required to be, and are not, filed with the Commission, either as part of this Registration Statement or as prospectuses or prospectus supplements pursuant to Rule 424 under the Securities Act. These documents, and the documents incorporated by reference in this Registration Statement pursuant to Item 3 of Part II of this Form S-8, taken together, constitute a prospectus that meets the requirements of Section 10(a) of the Securities Act.

     

    3


     

    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

    Item 3. Incorporation of Documents by Reference.

    The following documents, which have been filed with the Commission by the Company pursuant to the Securities Act and the Securities Exchange Act of 1934, as amended (the “Exchange Act”), as applicable, are hereby incorporated by reference in, and shall be deemed to be a part of, this Registration Statement:

    •
    the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Commission on March 22, 2023 (including, for the avoidance of doubt, the information specifically incorporated by reference in the Company’s Form 10-K from the Company’s Definitive Proxy Statement for the 2025 Annual Meeting of Stockholders, filed with the Commission on April 23, 2025);
    •
    the Company’s Quarterly Reports on Form 10-Q for the quarters ended March 31, 2025 and June 30, 2025, filed with the Commission on May 8, 2025 and August 6, 2025, respectively;
    •
    our Current Reports on Form 8-K filed with the SEC on January 3, 2025, February 20, 2025, June 9, 2025, June 25, 2025 and August 6, 2025 (only Item 8.01); and
    •
    the description of the Company’s common stock in the Company’s Registration Statement on Form 8-A (File No. 001-35005) filed with the Commission on December 10, 2010, including any amendment or report filed by the Company for the purpose of updating such description, including Exhibit 4.2 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, filed with the Commission on March 22, 2023.

    All documents subsequently filed by the Company pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act prior to the filing of a post-effective amendment to this Registration Statement that indicates that all of the shares of common stock registered hereunder have been sold or that deregisters all of such shares then remaining unsold, shall be deemed to be incorporated by reference into this Registration Statement and to be a part hereof from the respective dates of filing of such documents, except as to any portion of any future annual or quarterly report to stockholders or document or current report furnished under current Item 2.02 or 7.01 or any related Item 9.01 of Form 8-K that is not deemed filed under such provisions.

    Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein, or in any other subsequently filed document that also is or is deemed to be incorporated by reference herein, modifies or supersedes such earlier statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

    You may request a copy of these filings, at no cost, by writing or telephoning the Company at:

    Two Tower Place, 7th Floor

    South San Francisco, California 94080

    Telephone: (833) 509-4583

    Attn: Corporate Secretary

    You should rely only on the information provided or incorporated by reference in this Registration Statement or any related prospectus. The Company has not authorized anyone to provide you with different information. You should not assume that the information in this Registration Statement or any related prospectus is accurate as of any date other than the date on the front of the document.

    Item 4. Description of Securities.

    Not applicable.

    Item 5. Interests of Named Experts and Counsel.

    Not applicable.

    II-1


     

    Item 6. Indemnification of Directors and Officers.

    Not applicable.

    Item 7. Exemption from Registration Claimed.

    Not applicable.

    Item 8. Exhibits.

    See the Exhibit Index on the page immediately preceding the signatures to this Registration Statement for a list of exhibits filed as part of this Registration Statement, which Exhibit Index is incorporated herein by reference.

    Item 9. Undertakings.

    Not required to be filed with this Registration Statement pursuant to General Instruction E to Form S-8.

    II-2


     

    EXHIBIT INDEX

     

    Exhibit

    No.

     

    Description

     

     

     

      4.1

     

    Sixth Amended and Restated Certificate of Incorporation of Assembly Biosciences, Inc. (incorporated by reference to Exhibit 3.1 of the Registrant’s Annual Report on Form 10-K filed with the Commission on March 28, 2024).

     

     

     

      4.2

     

    Certificate of Amendment to Sixth Amended and Restated Certificate of Incorporation of Assembly Biosciences, Inc., dated February 9, 2024 (incorporated by reference to Exhibit 3.1 to the Registrant's Current report on Form 8-K filed on February 13, 2024).

     

     

     

      4.3

     

    Amended and Restated Bylaws of Assembly Biosciences, Inc., as amended on December 12, 2024 (incorporated by reference to Exhibit 3.1 of the Registrant’s Current Report on Form 8-K filed with the Commission on December 13, 2024).

     

     

     

      4.4

     

    Specimen Common Stock Certificate of Assembly Biosciences, Inc. (incorporated by reference to Exhibit 4.1 of the Registrant’s Registration Statement on 10-K filed with the Commission on March 20, 2025).

     

     

     

      5.1

     

    Opinion of Skadden, Arps, Slate, Meagher & Flom LLP.

     

     

     

    23.1

     

    Consent of Skadden, Arps, Slate, Meagher & Flom LLP (included in Exhibit 5.1).

     

     

     

    23.2

     

    Consent of Independent Registered Public Accounting Firm.

     

     

     

    24.1

     

    Power of Attorney (included on the signature page of this Registration Statement).

     

     

     

    99.1

     

    Assembly Biosciences, Inc. Amended and Restated 2018 Stock Incentive Plan (incorporated by reference to Exhibit 10.1 of the Registrant’s Current Report on Form 8-K filed with the Commission on June 3, 2024).

     

     

     

    99.2

     

    Amendment No. 1 to Assembly Biosciences, Inc. Amended and Restated 2018 Stock Incentive Plan (incorporated by reference to Exhibit 10.1 of the Registrant’s Current Report on Form 8-K filed with the Commission on June 9, 2025).

     

     

     

    99.3

     

    Amendment No. 2 to Assembly Biosciences, Inc. Amended and Restated 2018 Stock Incentive Plan (incorporated by reference to Exhibit 10.2 of the Registrant’s Current Report on Form 8-K filed with the Commission on June 9, 2025).

     

     

     

    99.4

     

    Assembly Biosciences, Inc. Second Amended and Restated 2018 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.2 of the Registrant's Current Report on Form 8-K filed with the Commission on June 3, 2024).

     

     

     

    99.5

     

    Amendment No. 1 to Assembly Biosciences, Inc. Second Amended and Restated 2018 Stock Incentive Plan (incorporated by reference to Exhibit 10.3 of the Registrant’s Current Report on Form 8-K filed with the Commission on June 9, 2025).

     

     

     

     107

     

    Filing Fees.

     

    II-3


     

    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of South San Francisco, State of California, on August 6, 2025.

     

    Assembly Biosciences, Inc.

    By:

    /s/ Jason A. Okazaki

    Jason A. Okazaki

    Chief Executive Officer and President

     

    II-4


     

    POWER OF ATTORNEY

    We, the undersigned officers and directors of Assembly Biosciences, Inc., hereby severally constitute and appoint Jason A. Okazaki and John O. Gunderson, and each of them singly (with full power to each of them to act alone), our true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution in each of them for him/her and in his/her name, place and stead, and in any and all capacities, to sign for us and in our names in the capacities indicated below any and all amendments (including post-effective amendments) to this registration statement on Form S-8, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite or necessary to be done in and about the premises, as full to all intents and purposes as he/she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or any of them, or their or his/her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons on August 6, 2025 in the capacities indicated.

     

    Signature

    Title

    /s/ Jason A. Okazaki

    Director, Chief Executive Officer and President

    (Principal Executive Officer)

    Jason A. Okazaki

    /s/ Jeanette M. Bjorkquist

     

    Vice President, Finance

    (Principal Financial Officer and Principal Accounting Officer)

    Jeanette M. Bjorkquist

     

    /s/ William R. Ringo, Jr.

    Chairman of the Board

    William R. Ringo, Jr.

     

     

     

    /s/ Anthony E. Altig

    Director

    Anthony E. Altig

    /s/ Tomas Cihlar, Ph.D.

     

    Director

    Thomas Cihlar, Ph.D.

     

     

     

     

     

    /s/ Gina Consylman

    Director

    Gina Consylman

     

     

     

    /s/ Robert D. Cook II

     

    Director

    Robert D. Cook II

     

     

     

     

     

    /s/ Michael Houghton, Ph.D.

    Director

    Michael Houghton, Ph.D.

     

     

     

    /s/ Lisa R. Johnson-Pratt, M.D.

    Director

    Lisa R. Johnson-Pratt, M.D.

     

     

     

    /s/ Susan Mahony, Ph.D.

    Director

    Susan Mahony, Ph.D.

     

    /s/ John G. McHutchison, A.O., M.D.

    Director

    John G. McHutchison, A.O., M.D.

     

     

     

     

    II-5


    Get the next $ASMB alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ASMB

    DatePrice TargetRatingAnalyst
    8/18/2025$50.00Buy
    H.C. Wainwright
    3/25/2025$31.00Buy
    Guggenheim
    9/20/2024$2.00 → $35.00Hold → Buy
    Jefferies
    9/13/2021$3.50Neutral
    HC Wainwright & Co.
    9/2/2021Outperform → Market Perform
    William Blair
    More analyst ratings

    $ASMB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    PFO and PAO Bjorkquist Jeanette M was granted 300 shares, increasing direct ownership by 6% to 5,097 units (SEC Form 4)

    4 - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Issuer)

    6/17/25 4:05:04 PM ET
    $ASMB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Houghton Michael

    4 - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Issuer)

    6/9/25 4:05:21 PM ET
    $ASMB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Mahony Susan

    4 - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Issuer)

    6/9/25 4:05:19 PM ET
    $ASMB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASMB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright resumed coverage on Assembly Biosciences with a new price target

    H.C. Wainwright resumed coverage of Assembly Biosciences with a rating of Buy and set a new price target of $50.00

    8/18/25 8:55:27 AM ET
    $ASMB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Guggenheim initiated coverage on Assembly Biosciences with a new price target

    Guggenheim initiated coverage of Assembly Biosciences with a rating of Buy and set a new price target of $31.00

    3/25/25 8:26:24 AM ET
    $ASMB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Assembly Biosciences upgraded by Jefferies with a new price target

    Jefferies upgraded Assembly Biosciences from Hold to Buy and set a new price target of $35.00 from $2.00 previously

    9/20/24 7:32:14 AM ET
    $ASMB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASMB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Houghton Michael bought $49,998 worth of shares (3,202 units at $15.61) (SEC Form 4)

    4 - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Issuer)

    12/31/24 4:24:14 PM ET
    $ASMB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Gilead Sciences, Inc. bought $20,098,464 worth of shares (940,499 units at $21.37), increasing direct ownership by 74% to 2,209,471 units (SEC Form 4)

    4 - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Issuer)

    12/23/24 8:26:39 PM ET
    $ASMB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Schornstein Alexander bought $371,994 worth of shares (25,000 units at $14.88), increasing direct ownership by 4% to 728,113 units (SEC Form 4)

    4 - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Issuer)

    11/26/24 9:15:02 AM ET
    $ASMB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASMB
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by Assembly Biosciences Inc.

    SCHEDULE 13G - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Subject)

    8/18/25 5:52:05 PM ET
    $ASMB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Assembly Biosciences Inc.

    SCHEDULE 13G/A - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Subject)

    8/18/25 4:18:39 PM ET
    $ASMB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by Assembly Biosciences Inc.

    SCHEDULE 13G - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Subject)

    8/15/25 6:56:48 PM ET
    $ASMB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASMB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Assembly Biosciences Announces Pricing of $175 Million in Equity Financings

    SOUTH SAN FRANCISCO, Calif., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. ("Assembly Bio") (NASDAQ:ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced the pricing of an underwritten, registered offering (the "offering") of an aggregate of 5,591,840 shares of common stock and pre-funded warrants to purchase up to 1,040,820 shares of common stock, together with accompanying Class A and Class B warrants to purchase up to an aggregate of 6,632,660 shares of common stock at a combined price per share of common stock and accompanying Class A warrant and Class B warrant of $19.60 and a combined price per pre-funded wa

    8/8/25 8:05:00 AM ET
    $ASMB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Assembly Biosciences Reports Positive Interim Results from Phase 1b Clinical Study of Long-Acting Helicase-Primase Inhibitor Candidate ABI-5366 Showing Reductions in Viral Shedding Rate and Genital Lesion Rate in Recurrent Genital Herpes

    – 94% reduction in HSV-2 shedding rate and 98% reduction in high viral load shedding rate, both statistically significant, observed in cohort evaluating 350 mg weekly oral dose compared to placebo over 29-day evaluation period – – 94% reduction in genital lesion rate, also statistically significant, observed with 350 mg weekly oral dose compared to placebo over same period – – Favorable safety and tolerability profile observed in the first two cohorts evaluating weekly oral doses of ABI-5366 – SOUTH SAN FRANCISCO, Calif., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a biotechnology company developing innovative therapeutics targeting serious viral di

    8/8/25 8:00:00 AM ET
    $ASMB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Assembly Biosciences Reports Interim Phase 1a Data from Clinical Study of Oral Entry Inhibitor Candidate ABI-6250 for Hepatitis Delta Virus

    – Data to date in single- and multiple-ascending dose cohorts of healthy participants demonstrate a four-day half-life for ABI-6250, supporting target daily oral dosing profile and dose-dependent elevations in biomarker of target engagement – – Further pharmacological assessment to be conducted in parallel with Phase 2 preparation – SOUTH SAN FRANCISCO, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced interim data from several cohorts from the ongoing Phase 1a clinical trial of ABI-6250, the company's orally bioavailable, small molecule hepatitis

    8/6/25 4:05:00 PM ET
    $ASMB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASMB
    Leadership Updates

    Live Leadership Updates

    View All

    Assembly Biosciences Names Anuj Gaggar, MD, PhD, as Chief Medical Officer

    -- Dr. Gaggar is an experienced industry executive with substantial infectious disease expertise and proven record of successfully leading early- and clinical-stage antiviral programs -- SOUTH SAN FRANCISCO, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, today announced that Anuj Gaggar, MD, PhD, has joined the company as chief medical officer. Dr. Gaggar is an infectious disease specialist and seasoned executive whose experience has focused on the development of new therapies in viral diseases including chronic hepatitis B virus (HBV), hepatitis C vi

    11/8/23 8:00:00 AM ET
    $ASMB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Assembly Biosciences Nominates First Herpesvirus Development Candidate ABI-5366, a Long-Acting HSV-2 Helicase Inhibitor Targeting High-Recurrence Genital Herpes

    −ABI-5366 Demonstrates Favorable Profile for a Long-Acting Therapeutic in Preclinical Studies −IND-Enabling Studies Initiating for 5366, Supporting Anticipated IND/CTA Filing in 1H2024 SOUTH SAN FRANCISCO, Calif., Feb. 15, 2023 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a clinical-stage biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, today announced the selection of development candidate ABI-5366 (5366) to progress to IND-enabling studies for its long-acting herpes simplex virus type 2 (HSV-2) helicase inhibitor program. 5366 is the first development candidate from Assembly Bio's discovery pipeline nominated for adv

    2/15/23 8:00:00 AM ET
    $ASMB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Carver Biosciences Announces Appointment of Three Members to its Scientific Advisory Board

    Carver Biosciences, Inc., a biotech company focused on the development of CRISPR/Cas13 antivirals, today announced the formation of its Scientific Advisory Board (SAB). Cameron Myhrvold Ph.D., co-founder of Carver will serve as the chairman of the SAB. Additional appointments include Uri Lopatin, M.D., Olivia Merkel, Ph.D., and Neville Sanjana, Ph.D. "I am thrilled to have Dr. Lopatin, Dr. Merkel and Dr. Sanjana join our advisory board," said Dr. Walter Strapps, co-founder and CEO of Carver. "Along with Dr. Myhrvold, these scientific leaders will help us shape our pipeline and advance our programs into the clinic." Uri Lopatin, M.D. Dr. Lopatin is a serial biotech entrepreneur who founde

    1/17/23 7:00:00 AM ET
    $ASMB
    $PRDS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medicinal Chemicals and Botanical Products

    $ASMB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Assembly Biosciences Inc.

    SC 13G - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Subject)

    11/14/24 3:22:29 PM ET
    $ASMB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Assembly Biosciences Inc.

    SC 13D/A - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Subject)

    6/24/24 4:28:09 PM ET
    $ASMB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Assembly Biosciences Inc.

    SC 13D/A - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Subject)

    6/20/24 8:35:37 PM ET
    $ASMB
    Biotechnology: Pharmaceutical Preparations
    Health Care